Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer.
Franco
F
Muggia
Timothy
T
Cannon
Tamar
T
Safra
John
J
Curtin
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000068258:Bevacizumab; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy; D018450:Disease Progression; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy*; D017671:Platinum Compounds / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects*; D012008:Recurrence; D051437:Renal Insufficiency / Q000139:chemically induced / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017671:Platinum Compounds; C506643:liposomal doxorubicin; D000068258:Bevacizumab; D011092:Polyethylene Glycols; D004317:Doxorubicin